Compare STIM & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STIM | XTNT |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 88.7M |
| IPO Year | 2018 | 2009 |
| Metric | STIM | XTNT |
|---|---|---|
| Price | $1.48 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | $1.50 |
| AVG Volume (30 Days) | ★ 1.4M | 99.1K |
| Earning Date | 03-17-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.25 | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | $52,776,000.00 | ★ $53,337,000.00 |
| Revenue This Year | $11.51 | $15.08 |
| Revenue Next Year | $11.63 | N/A |
| P/E Ratio | ★ N/A | $19.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.80 | $0.34 |
| 52 Week High | $5.05 | $0.95 |
| Indicator | STIM | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 43.08 |
| Support Level | $1.22 | $0.55 |
| Resistance Level | $1.79 | $0.68 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 99.40 | 16.98 |
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.